Debrisoquine oxidation in an Australian population

• Published in: British journal of clinical pharmacology Vol. 21; no. 5; pp. 465 - 471
• Main Authors: Peart, GF, Boutagy, J, Shenfield, GM
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-05-1986; Blackwell Science
• Subjects: Acetylation; Adolescent; Adult; Australia; Biological and medical sciences; Debrisoquin - metabolism; European Continental Ancestry Group; Female; General pharmacology; Genetic Variation; Humans; Isoquinolines - metabolism; Male; Medical sciences; Middle Aged; Oxidation-Reduction; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Phenotype; Sulfamethazine - metabolism; Urine - analysis; Australia; Human; Pharmacogenetics; Acetylator phenotype; Interindividual comparison; Oxidation; Acetylation; Australia; Pharmacokinetics; Oceania
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/j.1365-2125.1986.tb02827.x

The standard laboratory method for determination of debrisoquine phenotype has been modified and shortened with no loss of sensitivity. Debrisoquine metabolic ratios (MR) at 4 and 8 h showed excellent correlation indicating that collection time can also be shortened. Same day phenotyping is therefore possible. One hundred normal, Caucasian Australian subjects were phenotyped (46 males, 54 females) and 6% were poor metabolisers (PM) of debrisoquine. Fifty of the original subjects were also acetylation phenotyped and 34% were fast and 66% slow acetylators. One PM of debrisoquine was a fast acetylator of sulphadimidine and four PM were slow acetylators. This was a non‐ significant association.